newsfilter
← Latest News
Business Wire·

Arena Reports Third Quarter Financial Results and Key Program Updates

– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout – First participant randomized in the Phase 2 trial for temanogrel in Raynaud's phenomenon secondary to systemic sclerosis – Strong liquidity position to support